Role of glucocorticoids in the regulation of dopaminergic neurotransmission

Polish Journal of Pharmacology

Volumn 55, Issue 5, 2003, Pages 667-674

  Czyrak, Anna ^a   Maćkowiak, Marzena ^a   Chocyk, Agnieszka ^a   Fijał, Katarzyna ^a   Wedzony, Krzysztof ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Addiction; Corticosterone; Dopamine; Dopaminergic receptors; Stress; Tyrosine hydroxylase

Indexed keywords

CORTICOSTERONE; DOPAMINE 1 RECEPTOR; GLUCOCORTICOID; PSYCHOSTIMULANT AGENT; TYROSINE 3 MONOOXYGENASE;

CELL ACTIVATION; CORTICOSTERONE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG ABUSE; DRUG SENSITIVITY; DRUG SENSITIZATION; ENZYME SYNTHESIS; EXPERIMENTAL ANIMAL; HYPOTHALAMUS PERIVENTRICULAR NUCLEUS; INTRACELLULAR TRANSPORT; NERVE ENDING; NONHUMAN; PERIKARYON; PROTEIN FUNCTION; PROTEIN TRANSPORT; REVIEW; STRESS;

ANIMALS; DOPAMINE; GLUCOCORTICOIDS; HUMANS; NEUROTRANSMITTER AGENTS; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2;

EID: 0346957395     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Angulo J.A., McEwen B.S.: Molecular aspects of neuropeptide regulation and function in the corpus striatum and nucleus accumbens. Brain Res. Rev., 1994, 19, 1-28.
2. Antoni F.A.: Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front. Neuroendocrinol., 1993, 14, 76-122.
3. Beitner-Johnson D., Guitart X., Nestler E.J.: Neurofilament proteins and the mesolimbic dopamine system: common regulation by chronic morphine and chronic cocaine in the rat ventral tegmental area. J. Neurosci., 1992, 12, 2165-2176.
4. Biron D., Dauphin C., Di Paolo T.: Effects of adrenalectomy and glucocorticoids on rat brain dopamine receptors. Neuroendocrinology, 1992, 55, 468-476.
5. Bjijou Y., Stinus L., Le Moal M., Cador M.: Evidence for selective involvement of dopamine D1 receptors of the ventral tegmental area in the behavioral sensitization induced by intra-ventral tegmental area injections of D-amphetamine. J. Pharmacol. Exp. Ther., 1996, 277, 1177-1187.
6. Czyrak A., Chocyk A.: Search for the presence of glucocorticoid receptors in dopaminergic neurons of rat ventral tegmental area and substantia nigra. Pol. J. Pharmacol., 2001, 53, 681-684.
7. Czyrak A., Chocyk A., Maćkowiak M., Fijał K., Wedzony K.: Distribution of dopamine D1 receptors in the nucleus paraventricularis of the hypothalamus in rats: an immunohistochemical study. Mol. Brain Res., 2000, 85, 209-217.
8. Czyrak A., Maćkowiak M., Chocyk A., Fijał K., Gadek-Michalska A., Wedzony K.: 8-OHDPAT-induced disruption of prepulse inhibition in rats is attenuated by prolonged corticosterone treatment. Neuropsychopharmacology, 2003, 28, 1300-1310.
9. Czyrak A., Maćkowiak M., Chocyk A., Fijał K., Tokarski K., Bijak M., Wedzony K.: Prolonged corticosterone treatment alters the responsiveness of 5-HT1A receptors to 8-OH-DPAT in rat CA1 hippocampal neurons. Naunyn-Schmied. Arch. Pharmacol., 2002, 366, 357-367.
10. Czyrak A., Maćkowiak M., Fijał K., Chocyk A., Wedzony K.: Impact of metyrapone on MK-801-induced alterations in the rat dopamnine D1 receptors. Pol. J. Pharmacol., 1997, 49, 305-316.
11. Czyrak A., Wedzony K., Michalska B., Fijał K., Dziedzicka-Wasylewska M., Maćkowiak M.: The corticosterone synthesis inhibitor metyrapone decreases dopamine D1 receptors in the rat brain. Neuroscience, 1997, 79, 489-495.
12. Davidoff S.A., Benes F.M.: High-resolution Scatchard. analysis shows D1 receptor binding on pyramidal and nonpyramidal neurons. Synapse, 1998, 28, 83-90.
13. de Kloet E.R., Reul J.M., Sutanto W.: Corticosteroids and the brain. J. Steroid Biochem. Mol. Biol., 1990, 37, 387-394.
14. Deroche V., Piazza P.V., Maccari S., Le Moal M., Simon H.: Repeated corticosterone administration sensitizes the locomotor response to amphetamine. Brain Res., 1992, 584, 309-313.
15. Deutch A.Y.: Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's disease. J. Neural Transm.-Gen. Sect., 1993, 91, 197-221.
16. Eaton M.J., Cheung S., Moore K.E., Lookingland K.J.: Dopamine receptor-mediated regulation of corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Res., 1996, 738, 60-66.
17. Erb S., Shaham Y., Stewart J.: The role of corticotropin-releasing factor and corticosterone in stress- and cocaine-induced relapse to cocaine seeking in rats. J. Neurosci., 1998, 18, 5529-5536.
18. Fremeau R.T. Jr., Duncan G.E., Fornaretto M.G., Dearry A., Gingrich J.A., Breese G.R., Caron M.G.: Localization of D1 dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission. Proc. Nat. Acad. Sci. USA, 1991, 88, 3772-3776.
19. Grace A.A.: Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience, 1991, 41, 1-24.
20. Jehan F., Neveu I., Naveilhan P., Brachet P., Wion D.: Complex interactions among second messenger pathways, steroid hormones, and protooncogenes of the Fos and Jun families converge in the regulation of the nerve growth factor gene. J. Neurochem., 1993, 60, 1843-1853.
21. Joels M., de Kloet ER.: Control of neuronal excitability by corticosteroid hormones. Trends Neurosci., 1992, 15, 25-30.
22. Kalivas P.W.: Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res. Rev., 1993, 18, 75-113.
23. Kalivas P.W., Stewart J.: Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res. Rev., 1991, 16, 223-244.
24. Karanth S., Linthorst A.C., Stalla G.K., Barden N., Holsboer F., Reul J.M.: Hypothalamic-pituitary-adrenocortical axis changes in a transgenic mouse with impaired glucocorticoid receptor function. Endocrinology, 1997, 138, 3476-3485.
25. Koob G.F., Sanna P.P., Bloom F.E.: Neuroscience of addiction. Neuron, 1998, 21, 467-476.
26. Kovacs K.J., Arias C., Sawchenko P.E.: Protein synthesis blockade differentially affects the stress-induced transcriptional activation of neuropeptide genes in parvocellular neurosecretory neurons. Mol. Brain Res., 1998, 54, 85-91.
27. Kovacs K.J., Sawchenko P.E.: Sequence of stress-induced alterations in indices of synaptic and transcriptional activation in parvocellular neurosecretory neurons. J. Neurosci., 1996, 16, 262-273.
28. Nestler E.J.: Molecular mechanisms of drug addiction. J. Neurosci., 1992, 12, 2439-2450.
29. Ortiz J., DeCaprio J.L., Kosten T.A., Nestler E.J.: Strain-selective effects of corticosterone on locomotor sensitization to cocaine and on levels of tyrosine hydroxylase and glucocorticoid receptor in the ventral tegmental area. Neuroscience, 1995, 67, 383-397.
30. Piazza P.V., Le Moal M.: Glucocorticoids as a biological substrate of reward: physiological and pathophysiological implications. Brain Res. Rev., 1997, 25, 359-372.
31. Piazza P.V., Maccari S., Deminiere J.M., Le Moal M., Mormede P., Simon H.: Corticosterone levels determine individual vulnerability to amphetamine self-administration, Proc. Nat. Acad. Sci. USA, 1991, 88, 2088-2092.
32. Piazza P.V., Marinelli M., Jodogne C., Deroche V, Rouge-Pont F., Maccari S., Le Moal M., Simon H.: Inhibition of corticosterone synthesis by metyrapone decreases cocaine-induced locomotion and relapse of cocaine self-administration. Brain Res., 1994, 658, 259-264.
33. Rastogi R.B., Singhal R.L.: Evidence for the role of adrenocortical hormones in the regulation of noradrenaline and dopamine metabolism in certain brain areas. Brit. J. Pharmacol., 1978, 62, 131-136.
34. Rivkees S.A., Lachowicz J.E.: Functional D1 and D5 dopamine receptors are expressed in the suprachiasmatic, supraoptic, and paraventricular nuclei of primates. Synapse, 1997, 26, 1-10.
35. Rouge-Pont F., Marinelli M., Le Moal M., Simon H., Piazza PN: Stress-induced sensitization and glucocorticoids. II. Sensitization of the increase in extracellular dopamine induced by cocaine depends on stress-induced corticosterone secretion. J. Neurosci., 1995, 15, 7189-7195.
36. Savasta M., Dubois A., Scatton B.: Autoradiographic localization of D1 dopamine receptors in the rat brain with [3H]SCH 23390. Brain Res., 1986, 375, 291-301.
37. Stewart J., Vezina P.: Microinjections of Sch-23390 into the ventral tegmental area and substantia nigra pars reticulata attenuate the development of sensitization to the locomotor activating effects of systemic amphetamine. Brain Res., 1989, 495, 401-406.
38. Trembleau A., Bloom F.E.: Subcellular localization of tyrosine hydroxylase (TH) gene transcripts: new insights into the pattern of TH gene expression in the locus coeruleus under pharmacological stimulation. Biol. Cell, 1998, 90, 39-51.
39. Vezina P.: D1 dopamine receptor activation is necessary for the induction of sensitization by amphetamine in the ventral tegmental area. J. Neurosci., 1996, 16, 2411-2420.
40. Vezina P., Stewart J.: The effect of dopamine receptor blockade on the development of sensitization to the locomotor activating effects of amphetamine and morphine. Brain Res., 1989, 499, 108-120.
41. Wedzony K., Czyrak A.: The role of corticosteroids in the acquisition of sensitization to locomotor stimulant effects of MK-801. Brain Res., 1994, 657, 351-356.
42. Wedzony K., Czyrak A.: Presence and function of dopamine D1 receptors in the rat ventral tegmental area. Pol. J. Pharmacol., 1997, 49, 277-281.
43. Wedzony K., Maćkowiak M., Zajaczkowski W., Fijał K., Chocyk A., Czyrak A.: WAY 100135, an antagonist of 5-HT1A serotonin receptors, attenuates psychotomimetic effects of MK-801. Neuropsychopharmacology, 2000, 23, 547-559.
44. Wolf M.E., White F.J., Hu X.T.: MK-801 prevents alterations in the mesoaccumbens dopamine system associated with behavioral sensitization to amphetamine. J. Neurosci., 1994, 14, 1735-1745.
45. Zhou Q.Y., Li C., Civelli O.: Characterization of gene organization and promoter region of the rat dopamine D1 receptor gene. J. Neurochem., 1992, 59, 1875-1883.